Larvol Delta - KEYNOTEG05-Different-Doses-of-BI1607-in-Combination-With-Pembrolizumab-and-Ipilimumab-in-Participants-With-Unresectable-or-Metastatic-Melanoma

BI-1607 - BioInvent

Yervoy (ipilimumab) - BMS

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT06784648

Nov 20, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next